NGLFINE Q4 FY26 Results & Earnings Analysis
Sentiment: Good (Confidence: medium)
Earnings Summary
NGL Fine-Chem delivered a strong recovery in FY26 with revenue up 36% YoY to ₹500.95cr and EBITDA margin expanding 531 bps to 14.51%. Q4 FY26 was particularly strong (+57% YoY revenue, +769 bps EBITDA margin). The recovery is volume-led and broad-based across geographies. Phase I capacity is operational; Phase II commissioning is slightly delayed to Q2 FY27. Partial price pass-through has been achieved, and management targets 15-18% EBITDA margins going forward. Regulated market (Europe, US) contributions are expected from H2 FY27 and FY28 respectively. Competitive intensity remains high, but product pipeline expansion (10 new APIs/year) and regulatory progress provide growth levers. Key near-term risks include input cost volatility, forex movements, and regulatory timelines.
Management Tone
- Prepared Remarks: Good — Prepared remarks highlighted a strong recovery with broad-based volume growth, margin expansion (EBITDA margin up 769 bps YoY), and progress on capacity expansion. Management conveyed confidence while acknowledging external cost pressures and a slight sequential margin dip.
- Q&A Session: Good — Q&A was detailed and constructive. Analysts probed on capacity, margins, competitive dynamics, and regulatory timelines. Management provided specific updates (e.g., partial price pass-through, Ph-II timeline, CEP filings) and maintained a balanced, confident tone without major red flags.
Revenue Growth Drivers
- Higher volumes across product portfolio and geographies, supported by improved capacity utilization (Phase I at 70-80%) and outsourcing of intermediates (~20% of requirement).
- Partial price pass-through secured in Q1 FY27 to offset cost inflation (freight, raw materials).
- Broad-based demand recovery across geographies (Latin America, etc.) and new customer additions (47 new customers in Q4).
Growth vs Margin Focus
Management emphasized volume-led growth while targeting EBITDA margin improvement to 15-18% range. They are balancing growth investments (capacity expansion, regulatory filings) with margin discipline.
About NGL Fine-Chem Limited
NGL Fine-Chem Limited (NGLFINE) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.